Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase i study

Luis Squiquera, Debra J. Taxman, Sarah A. Brendle, Roberto Torres, Jamie Sulley, Thomas Hodge, Neil Christensen, David Sidransky

Research output: Contribution to journalArticle

Abstract

Background: Human papillomaviruses (HPV), the causative agents of anogenital warts, are the most prevalent sexually transmitted infectious agents, and wart treatment poses a persistent challenge. We assessed the safety and efficacy of treating HPV with ranpirnase, an endoribonuclease from the northern leopard frog that has been used extensively in Phase III oncology trials. Methods: As initial verification of ranpirnase antiviral activity, we assessed its ability to eliminate papillomaviruses in cultured cells. To further assess its feasibility for treating anogenital warts in humans, we performed a Phase I study. Forty-two male volunteers with genital/ perianal warts were treated topically with three different formulations of 1 mg/ml ranpirnase. Patients were monitored for 8 weeks or until healing. Four patients with HIV were treated in accordance with the compassionate programme but were not evaluated. Results: In cultured cells, ranpirnase showed specific activity against HPV-11 with low toxicity (selectivity index >88). The broad applicability of ranpirnase for treating papillomaviruses was verified using the cottontail rabbit papillomavirus. In the clinical study, eight participants were lost-to-follow-up or discontinued due to protocol violation or non-compliance. Among 30 evaluable participants, topical ranpirnase was moderately well-tolerated, with discontinuation by 5 (16.7%) due to adverse reactions. Clinical healing was achieved by 25 participants (83.3%) and 50% improvement by the 5 discontinued participants (16.7%). The median time to clinical healing was 30 days. Conclusions: This study provides the first in vitro and clinical evidence of the antiviral efficacy of ranpirnase against HPV and supports assessment of ranpirnase in expanded clinical studies.

Original languageEnglish (US)
Pages (from-to)247-255
Number of pages9
JournalAntiviral Therapy
Volume22
Issue number3
DOIs
StatePublished - 2017
Externally publishedYes

Fingerprint

Warts
Cultured Cells
Antiviral Agents
Cottontail rabbit papillomavirus
Endoribonucleases
Human papillomavirus 11
Rana pipiens
Condylomata Acuminata
ranpirnase
Lost to Follow-Up
Volunteers
HIV
Safety

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase i study. / Squiquera, Luis; Taxman, Debra J.; Brendle, Sarah A.; Torres, Roberto; Sulley, Jamie; Hodge, Thomas; Christensen, Neil; Sidransky, David.

In: Antiviral Therapy, Vol. 22, No. 3, 2017, p. 247-255.

Research output: Contribution to journalArticle

Squiquera, L, Taxman, DJ, Brendle, SA, Torres, R, Sulley, J, Hodge, T, Christensen, N & Sidransky, D 2017, 'Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase i study', Antiviral Therapy, vol. 22, no. 3, pp. 247-255. https://doi.org/10.3851/IMP3133
Squiquera, Luis ; Taxman, Debra J. ; Brendle, Sarah A. ; Torres, Roberto ; Sulley, Jamie ; Hodge, Thomas ; Christensen, Neil ; Sidransky, David. / Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase i study. In: Antiviral Therapy. 2017 ; Vol. 22, No. 3. pp. 247-255.
@article{a8273be4e97441f99bd2504aafddcc31,
title = "Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase i study",
abstract = "Background: Human papillomaviruses (HPV), the causative agents of anogenital warts, are the most prevalent sexually transmitted infectious agents, and wart treatment poses a persistent challenge. We assessed the safety and efficacy of treating HPV with ranpirnase, an endoribonuclease from the northern leopard frog that has been used extensively in Phase III oncology trials. Methods: As initial verification of ranpirnase antiviral activity, we assessed its ability to eliminate papillomaviruses in cultured cells. To further assess its feasibility for treating anogenital warts in humans, we performed a Phase I study. Forty-two male volunteers with genital/ perianal warts were treated topically with three different formulations of 1 mg/ml ranpirnase. Patients were monitored for 8 weeks or until healing. Four patients with HIV were treated in accordance with the compassionate programme but were not evaluated. Results: In cultured cells, ranpirnase showed specific activity against HPV-11 with low toxicity (selectivity index >88). The broad applicability of ranpirnase for treating papillomaviruses was verified using the cottontail rabbit papillomavirus. In the clinical study, eight participants were lost-to-follow-up or discontinued due to protocol violation or non-compliance. Among 30 evaluable participants, topical ranpirnase was moderately well-tolerated, with discontinuation by 5 (16.7{\%}) due to adverse reactions. Clinical healing was achieved by 25 participants (83.3{\%}) and 50{\%} improvement by the 5 discontinued participants (16.7{\%}). The median time to clinical healing was 30 days. Conclusions: This study provides the first in vitro and clinical evidence of the antiviral efficacy of ranpirnase against HPV and supports assessment of ranpirnase in expanded clinical studies.",
author = "Luis Squiquera and Taxman, {Debra J.} and Brendle, {Sarah A.} and Roberto Torres and Jamie Sulley and Thomas Hodge and Neil Christensen and David Sidransky",
year = "2017",
doi = "10.3851/IMP3133",
language = "English (US)",
volume = "22",
pages = "247--255",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "3",

}

TY - JOUR

T1 - Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase i study

AU - Squiquera, Luis

AU - Taxman, Debra J.

AU - Brendle, Sarah A.

AU - Torres, Roberto

AU - Sulley, Jamie

AU - Hodge, Thomas

AU - Christensen, Neil

AU - Sidransky, David

PY - 2017

Y1 - 2017

N2 - Background: Human papillomaviruses (HPV), the causative agents of anogenital warts, are the most prevalent sexually transmitted infectious agents, and wart treatment poses a persistent challenge. We assessed the safety and efficacy of treating HPV with ranpirnase, an endoribonuclease from the northern leopard frog that has been used extensively in Phase III oncology trials. Methods: As initial verification of ranpirnase antiviral activity, we assessed its ability to eliminate papillomaviruses in cultured cells. To further assess its feasibility for treating anogenital warts in humans, we performed a Phase I study. Forty-two male volunteers with genital/ perianal warts were treated topically with three different formulations of 1 mg/ml ranpirnase. Patients were monitored for 8 weeks or until healing. Four patients with HIV were treated in accordance with the compassionate programme but were not evaluated. Results: In cultured cells, ranpirnase showed specific activity against HPV-11 with low toxicity (selectivity index >88). The broad applicability of ranpirnase for treating papillomaviruses was verified using the cottontail rabbit papillomavirus. In the clinical study, eight participants were lost-to-follow-up or discontinued due to protocol violation or non-compliance. Among 30 evaluable participants, topical ranpirnase was moderately well-tolerated, with discontinuation by 5 (16.7%) due to adverse reactions. Clinical healing was achieved by 25 participants (83.3%) and 50% improvement by the 5 discontinued participants (16.7%). The median time to clinical healing was 30 days. Conclusions: This study provides the first in vitro and clinical evidence of the antiviral efficacy of ranpirnase against HPV and supports assessment of ranpirnase in expanded clinical studies.

AB - Background: Human papillomaviruses (HPV), the causative agents of anogenital warts, are the most prevalent sexually transmitted infectious agents, and wart treatment poses a persistent challenge. We assessed the safety and efficacy of treating HPV with ranpirnase, an endoribonuclease from the northern leopard frog that has been used extensively in Phase III oncology trials. Methods: As initial verification of ranpirnase antiviral activity, we assessed its ability to eliminate papillomaviruses in cultured cells. To further assess its feasibility for treating anogenital warts in humans, we performed a Phase I study. Forty-two male volunteers with genital/ perianal warts were treated topically with three different formulations of 1 mg/ml ranpirnase. Patients were monitored for 8 weeks or until healing. Four patients with HIV were treated in accordance with the compassionate programme but were not evaluated. Results: In cultured cells, ranpirnase showed specific activity against HPV-11 with low toxicity (selectivity index >88). The broad applicability of ranpirnase for treating papillomaviruses was verified using the cottontail rabbit papillomavirus. In the clinical study, eight participants were lost-to-follow-up or discontinued due to protocol violation or non-compliance. Among 30 evaluable participants, topical ranpirnase was moderately well-tolerated, with discontinuation by 5 (16.7%) due to adverse reactions. Clinical healing was achieved by 25 participants (83.3%) and 50% improvement by the 5 discontinued participants (16.7%). The median time to clinical healing was 30 days. Conclusions: This study provides the first in vitro and clinical evidence of the antiviral efficacy of ranpirnase against HPV and supports assessment of ranpirnase in expanded clinical studies.

UR - http://www.scopus.com/inward/record.url?scp=85021725828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021725828&partnerID=8YFLogxK

U2 - 10.3851/IMP3133

DO - 10.3851/IMP3133

M3 - Article

C2 - 28121292

AN - SCOPUS:85021725828

VL - 22

SP - 247

EP - 255

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 3

ER -